A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Key Inclusion Criteria:

• Males or non-pregnant females aged between 18 and 80 years (inclusive) at time ofsigning the informed consent form (ICF)

• Biopsy-confirmed MASH (previously named NASH) with fibrosis stage F2 or F3 per NASHclinical research network (CRN) System and NAS ≥4, with a score of at least 1 ineach of steatosis, ballooning degeneration, and lobular inflammation or NAS <4and/or a ballooning degradation score of 0 with fibrosis stage F3 and a score of atleast 1 in steatosis. A historical biopsy must be within 6 months of screening visit (with additional requirements).

• Body mass index (BMI) at screening ≥25.0 kilograms (kg)/meters squared (m^2) (≥23kg/m^2 for Asian countries)

Key Exclusion Criteria:

• Chronic liver diseases other than MASH/NASH

• Evidence of cirrhosis on screening liver biopsy

• Have type 1 diabetes or poorly controlled type 2 diabetes

• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥250 units perliter (U/L)

• Participants taking vitamin E (>400 international units [IU]/day) or pioglitazonemust be on stable dose for at least 6 months prior to screening

Other inclusion and exclusion criteria may apply.